Literature DB >> 25589214

Resistant hypertension: do all definitions describe the same patients?

L Boswell1, J Pascual2, A Oliveras2.   

Abstract

Resistant hypertension (RH) is defined as blood pressure (BP) that remains ⩾140 and/or 90 mm Hg despite therapy with ⩾3 full-dose antihypertensive drugs (classical definition=CD). A definition proposed subsequently (new definition=ND) includes patients requiring ⩾4 drugs irrespective of BP values. We aimed to evaluate whether both definitions characterize the same kind of patients.One hundred and twenty-four consecutively attended patients with RH were classified into two groups according to their BP control: 66 patients had non-controlled BP (all those who met the CD criteria plus a few patients who met the ND criteria); 58 patients had controlled BP (all with RH according to the ND). Clinical, laboratory and office BP data were recorded. RH patients with non-controlled BP were more frequently diabetic (72% vs 49%), and had higher plasmatic glucose (149 vs 130 mg dl(-1)), cholesterol (179 vs 164 mg dl(-1)), low-density lipoprotein (LDL)-cholesterol (107 vs 95 mg dl(-1)) and triglyceride (169 vs 137 mg dl(-1)) levels; P<0.05 for all comparisons. In multivariate logistic regression analysis, the variables that independently associated with non-controlled BP were diabetes (P=0.001) and higher LDL-cholesterol (P=0.007).We conclude that, although both cohorts of patients are phenotypically quite similar, uncontrolled RH patients have higher prevalence of diabetes mellitus and higher LDL-cholesterol levels than controlled RH patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25589214     DOI: 10.1038/jhh.2014.128

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  24 in total

1.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Authors:  William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

Review 2.  Recommendations for chamber quantification.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack Shanewise; Scott Solomon; Kirk T Spencer; Martin St John Sutton; William Stewart
Journal:  Eur J Echocardiogr       Date:  2006-02-02

3.  2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stephane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  Blood Press       Date:  2013-12-20       Impact factor: 2.835

Review 4.  [Evaluation and management of hypertension in Spain. A consensus guide].

Authors:  Alejandro de la Sierra; Manuel Gorostidi; Rafael Marín; Josep Redón; José R Banegas; Pedro Armario; Juan García Puig; Julio Zarco; José L Llisterri; Carlos Sanchís; Benjamín Abarca; Vicente Palomo; Ramón Gomis; Alfonso Otero; Fernando Villar; Jesús Honorato; Juan Tamargo; José M Lobos; Juan Macías-Núñez; Antonio Sarría; Pedro Aranda; Luis M Ruilope
Journal:  Med Clin (Barc)       Date:  2008-06-21       Impact factor: 1.725

5.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

6.  Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Authors:  Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky
Journal:  Hypertension       Date:  2011-05-02       Impact factor: 10.190

7.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

8.  Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension?

Authors:  Elizabeth S Muxfeldt; Gil F Salles
Journal:  J Hypertens       Date:  2008-05       Impact factor: 4.844

9.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension.

Authors:  Gil F Salles; Claudia R L Cardoso; Elizabeth S Muxfeldt
Journal:  Arch Intern Med       Date:  2008-11-24

10.  Refractory hypertension: definition, prevalence, and patient characteristics.

Authors:  Maria Czarina Acelajado; Roberto Pisoni; Tanja Dudenbostel; Louis J Dell'Italia; Falynn Cartmill; Bin Zhang; Stacey S Cofield; Suzanne Oparil; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-15       Impact factor: 3.738

View more
  4 in total

Review 1.  Resistant Hypertension: A Real Entity Requiring Special Treatment?

Authors:  Stefano Taddei; Rosa Maria Bruno
Journal:  Eur Cardiol       Date:  2016-08

2.  Resistant Hypertension: A Real Entity or a Phantom Diagnosis?

Authors:  Costas Thomopoulos; George Skalis; Thomas Makris
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-17       Impact factor: 3.738

3.  Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.

Authors:  Elizabeth do Espirito Santo Cestário; Letícia Aparecida Barufi Fernandes; Luiz Tadeu Giollo-Júnior; Jéssica Rodrigues Roma Uyemura; Camila Suemi Sato Matarucco; Manoel Idelfonso Paz Landim; Luciana Neves Cosenso-Martin; Lúcia Helena Bonalume Tácito; Heitor Moreno; José Fernando Vilela-Martin; Juan Carlos Yugar-Toledo
Journal:  Trials       Date:  2018-02-12       Impact factor: 2.279

Review 4.  The highly neglected burden of resistant hypertension in Africa: a systematic review and meta-analysis.

Authors:  Jobert Richie N Nansseu; Jean Jacques N Noubiap; Michel K Mengnjo; Leopold Ndemnge Aminde; Mickael Essouma; Ahmadou M Jingi; Jean Joel R Bigna
Journal:  BMJ Open       Date:  2016-09-20       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.